Motco Has $7.58 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Motco lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.2% during the 4th quarter, HoldingsChannel reports. The fund owned 38,561 shares of the medical research company’s stock after purchasing an additional 839 shares during the period. Motco’s holdings in IQVIA were worth $7,578,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Capital Performance Advisors LLP bought a new position in shares of IQVIA during the 3rd quarter worth approximately $27,000. Avior Wealth Management LLC boosted its position in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Synergy Asset Management LLC purchased a new stake in IQVIA during the 4th quarter worth about $33,000. Assetmark Inc. increased its holdings in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the period. Finally, Ashton Thomas Securities LLC bought a new stake in IQVIA during the third quarter valued at approximately $57,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Leerink Partners reiterated an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Morgan Stanley raised their price target on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Bank of America reduced their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. Finally, Barclays cut their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $251.22.

Insider Activity at IQVIA

In related news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of NYSE IQV opened at $186.40 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market cap of $32.82 billion, a P/E ratio of 24.85, a P/E/G ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a twelve month low of $184.66 and a twelve month high of $261.73. The stock has a 50 day moving average of $199.30 and a two-hundred day moving average of $215.26.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.